Epigenetics is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of diseases such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel market growth during the forecasted period.
Market Dynamics
Increasing prevalence of cancer is expected to drive the market growth during the forecast period.
According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).
Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.
The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.
Key features of the study:
- This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market
Detailed Segmentation:
- Global Epigenetics Drugs & Diagnostic Technologies Market, By Type:
- Epigenetic Drugs
- DNMT Inhibitors
- Azacitidine
- Decitabine
- HDAC Inhibitors
- Vorinostat
- Romidepsin
- Others
- Epigenetics Diagnostic Technologies
- DNAMethylation
- CHIP Technology
- Global Epigenetics Drugs & Diagnostic Technologies Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Regenacy Pharmaceuticals, Inc.*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Astex Pharmaceuticals
- 4SC AG
- CellCentric Ltd.
- Celleron Therapeutics Ltd.
- Bristol-Myers Squibb Company
- Oryzon Genomics S.A.
- ChromaMedicine, Inc.
- Epizyme, Inc.
- EpiGentek Group Inc.
"*" marked represents similar segmentation in other categories in the respective section.